Therapeutics/Diagnostics News

An adalimumab concentration threshold of 12.1 µg/mL “may be a target for therapeutic drug monitoring” to achieve complete fistula healing in perianal fistulizing Crohn’s disease, according to research in Clinical Gastroenterology and Hepatology.

The FDA has approved Skyrizi for the treatment of adult patients with moderate to severe ulcerative colitis, making it the first interleukin-23 specific inhibitor approved for both UC and Crohn’s disease, AbbVie reported.

In a Healio video exclusive, Mitchell L. Shiffman, MD, reports that U.S. patients with severe alcohol-associated hepatitis treated with larsucosterol experienced a “statistically significant” reduction in 90-day mortality — more than 50%.

In a Healio video exclusive, Anu Osinusi, MD, MPH, reported long-term bulevirtide monotherapy 2 mg and 10 mg remained safe and effective for chronic hepatitis D virus with improved biochemical, fibrosis and virologic markers at 144 weeks.

Treatment of chronic hepatitis C virus with direct-acting antivirals improved liver-related morbidity and survival, regardless of hepatocellular carcinoma, although patients aged older than 60 years should be monitored, a presenter noted.

Treatment with efruxifermin resulted in significant improvement in fibrosis at week 24 in patients with metabolic dysfunction-associated steatohepatitis, which was “sustained and expanded through week 96,” according to late-breaking data.

In a Healio video exclusive, Anu Osinusi, MD, MPH, reports that combination bulevirtide 10 mg with pegylated interferon alfa-2a for chronic hepatitis D virus infection resulted in the highest rates of undetectable HDV RNA through 48 weeks.

Denifanstat, a fatty acid synthase inhibitor, outperformed placebo in metabolic dysfunction-associated steatohepatitis resolution without worsening of fibrosis and fibrosis improvement, according to data presented at EASL Congress.

Elafibranor sustained biochemical response through week 78 in patients with primary biliary cholangitis and has a “potential beneficial effect” on itch-related quality of life, according to late-breaking data presented at EASL Congress.

WASHINGTON — A maintenance dose of subcutaneous Skyrizi may still induce clinical response in patients with ulcerative colitis who failed to achieve response after 12 weeks of IV induction, noted a presenter at Digestive Disease Week.